Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Buzz on the Bullboards: A recap of recent activity and stocks in focus

Last week witnessed a flurry of stock activity on Bay Street in Toronto and Wall Street in New York, as investors grappled with market volatility and shifting dynamics. After a major sell-off, markets have been on edge, closely monitoring corporate earnings and other key ...

Throw Everything You Know Out the Window

We’re on the precipice of a new adventure in the markets. Never before has so much data and information been available to investors around the globe. And yet, there’s no consensus on what’s going to happen. Not to me...

This Gold & Silver Exploration Company is Drilling THIS Summer in BC’s Golden Triangle

Six months after news of the COVID-19 virus first broke, financial markets around the world are finally starting to shake off the dust. And while a sense of normality may be starting to return, the blows it dealt will likely result in a few resilient bruises. Like the ov...

The Mid-May Déjà Vu in S&P 500

After a slight hesitation in yesterday's premarket, the S&P 500 hasn't much looked back since. And importantly, the credit markets – my biggest concern – had finally caught a bid. Their own reversal was less pronounced, making one question the corporate bond bulls' resolve rig...

Flying Under the Radar with a Possible COVID-19 Treatment

Investors would think a pharmaceutical company heading into Phase 2b/3 human trials for treating the third most malignant disease after lung cancer and pancreatic cancer would draw eyes from major players. If that same company announced it was embarking on Phase2b/3 human tri...